erlotinib hydrochloride has been researched along with Conus Medullaris Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lazzari, G; Lovecchio, M; Palazzo, C; Silvano, G | 1 |
1 other study(ies) available for erlotinib hydrochloride and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report.
Topics: Acute Disease; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Pain Management; Palliative Care; Quinazolines; Radiotherapy; Shock; Spinal Cord Compression | 2008 |